Imatinib, dasatinib, and ponatinib showed the weakened effect of growth inhibition and promoted apoptosis in cells with BCR::ABL1 compound mutations, which further verified the limitations of existing ATP-competitive TKIs targeting ABL1 for the treatment of CML patients with BCR::ABL1 compound mutations. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.